sodium-activated potassium channel inhibitor

This page covers all sodium-activated potassium channel inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Nav1.6, Nav1.5, KCNN4.

Targets

Nav1.6 · Nav1.5 · KCNN4

Marketed (1)

• VTS-K · Maimonides Medical Center · Neurology
  VTS-K is a small molecule that acts as a selective inhibitor of the sodium-activated potassium channel, Nav1.6.

Phase 3 pipeline (8)

• Group VTI · Kasr El Aini Hospital · Cardiovascular
  VTI-0521 is a small molecule inhibitor of the sodium-activated potassium channel, Nav1.5.
• SHR6390 Tablets · Jiangsu HengRui Medicine Co., Ltd. · Cardiovascular
  SHR6390 is a small molecule inhibitor of the sodium-activated potassium channel, Nav1.5.
• USL255 · Upsher-Smith Laboratories · Cardiovascular
  USL255 is a small molecule that acts as a selective inhibitor of the sodium-activated potassium channel, Nav1.5.
• TV-46000 · Teva Branded Pharmaceutical Products R&D, Inc. · Cardiovascular
  TV-46000 is a small molecule in development for the treatment of atrial fibrillation.
• TEV-56248 · Teva Branded Pharmaceutical Products R&D, Inc. · Neurology
  TEV-56248 is a small molecule drug that acts as a selective inhibitor of the sodium-activated potassium channel, KCNN4.
• TD-4208 · Mylan Inc. · Cardiovascular
  TD-4208 is a small molecule that acts as a selective inhibitor of the sodium-activated potassium channel, Nav1.5.
• TAK-816 · Takeda · Cardiovascular
  TAK-816 is a selective, reversible inhibitor of the sodium-activated potassium channel Nav1.5.
• TELMINUVO Tab. (80/2.5mg) · Chong Kun Dang Pharmaceutical · Cardiovascular
  Telminuvo is a selective inhibitor of the sodium-activated potassium channel, KCNN4.

Phase 2 pipeline (5)

• AN2690 · Pfizer · Neurology
  AN2690 is a small molecule that acts as a selective and potent inhibitor of the sodium-activated potassium channel, KCNN4.
• AGN-241751 · Syndeio Biosciences, Inc · Cardiovascular
  AGN-241751 is a small molecule inhibitor of the sodium-activated potassium channel, Nav1.5.
• CHF 5259 · Chiesi Farmaceutici S.p.A. · Cardiovascular
  CHF 5259 is a small molecule drug that acts as a selective inhibitor of the sodium-activated potassium channel, KCNN4.
• AN2690, 2.5% · Pfizer · Neurology
  AN2690 is a small molecule that acts as a selective and potent inhibitor of the sodium-activated potassium channel, KCNN4.
• ATX101 · Aurobac Therapeutics SAS · Cardiovascular
  ATX101 is a small molecule that acts as a selective inhibitor of the sodium-activated potassium channel, Nav1.5.